查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677231

個人化細胞和基因治療市場按治療類型、患者類型、治療領域和最終用戶分類 - 全球預測 2025-2030

Personalized Cell & Gene Therapies Market by Therapy Type, Patient Type, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

個人化細胞和基因治療市場預計在 2024 年達到 138.8 億美元，2025 年達到 163.0 億美元，到 2030 年將達到 414.9 億美元，複合年成長率為 20.01%。

主要市場統計數據
基準年 2024 年 138.8億美元
預計 2025 年 163億美元
預測年份 2030 414.9億美元
複合年成長率（%） 20.01％

在快速發展的醫學領域，個人化細胞和基因治療已成為一個變革前沿。這些創新療法所提供的高精度水平不僅重新定義了治療策略，也為患有各種疾病的患者帶來了前所未有的希望。在本介紹中，我們將仔細說明這些最先進治療如何透過根據個人基因和細胞特徵量身定做治療方案來改變醫療保健的未來。

生物醫學領域正從一刀切的解決方案轉向更細緻入微、針對病患的方法。進入個人化治療。這是治療方法。這種方法利用基因組學、生物技術和臨床創新的進步來治療複雜疾病，具有更高的療效和更少的副作用。

隨著產業的不斷進步，新的研究、先進的生物技術平台和策略夥伴關係關係的整合將在彌合臨床潛力與實用化之間的差距方面發揮關鍵作用。從傳統治療方法到個人化解決方案的進展不僅推動了臨床突破，而且還創造了新的市場機會。以下分析深入探討了影響這個令人興奮的產業未來的轉型動力、細分考量、區域影響、競爭格局和策略建議。

個人化醫療格局的變革

在過去的十年中，個人化細胞和基因治療的動態發展發生了重大轉變。幾個關鍵促進因素改變了治療方案的開發、檢驗和實施方式。這些促進因素包括高通量定序、先進的生物資訊學和基因組編輯技術的整合，這些技術共同實現了更精準的治療性介入。

研究突破已被證明對於從常見的免疫療法和化療轉向在分子層面的治療性介入方法轉變至關重要。細胞重編程和標靶基因修飾的革命性技術不僅提高了治療效果，而且擴大了可治療的病理頻譜。因此，曾經被認為超出許多患者承受能力的治療方法現在成為了可行的選擇，符合個人化醫療的原則。

世界各地的研究機構正迅速採用這些創新方法，利用學術研究機構和私人公司之間日益增多的合作。此次合作完善了藥物發現、臨床轉化和製造可擴展性的流程。監管機構也隨著這些創新而不斷發展，推出簡化的指導方針，以加快核准並確保安全。

這些變革不僅僅是技術上的，它們還重新定義了經營模式和市場策略。相關人員擴大投資於整合多組學資料的平台，以最佳化患者選擇並提高治療精度。診斷能力的提高將使我們能夠更詳細地了解疾病途徑，從而使製造商能夠設計出特異性針對細胞異常的治療方法。隨著這些快速進步，研究和臨床實踐之間的二分法正在迅速模糊，從而產生一種使患者和醫療保健提供者都受益的統一方法。

此外，創業投資和私人投資的激增增強了該行業對個人化醫療長期潛力的信心。這項投資加快了創新步伐，並確保尖端的科學研究轉化為切實的患者治療效果。隨著市場動態的不斷發展，該行業正在經歷從漸進式改進到徹底創新的根本性轉變，從而重新定義醫療保健的界限。

推動市場發展的關鍵細分洞察

要了解個人化細胞和基因治療市場的廣度和潛力，深入了解市場區隔是關鍵。我們從多個維度對市場進行了全面的分析，闡明了其複雜的結構和成長促進因素。首先，基於治療類型的細分區分了細胞療法和基因療法，為評估創新和應用提供了雙重框架。這種分類使相關人員能夠評估與每種治療方式相關的獨特的技術進步、監管途徑和臨床結果。

此外，根據患者類型進行市場細分，將市場分為成人市場、老年市場和兒童市場。此分類考慮了不同年齡層和臨床背景的不同治療需求，從而可以有效地為每個群體應用量身定做的治療方法。每種患者類別都表現出獨特的生理反應和疾病特徵，需要專門的治療策略和劑型。

此外，治療領域部分深入研究了疾病狀況，重點關注循環系統、血液學、免疫學、代謝紊亂、神經病學、腫瘤學和罕見疾病。這種多方面的分析不僅說明了個人化治療可以解決的疾病的多樣性，而且還強調了突破性治療方法最突出的特定領域。每個治療領域都有各自的挑戰和機會，這會影響投資重點和研究重點。

最後，按最終用戶進行細分考慮了該技術的各種機構和組織受益者，例如生物製藥公司、醫院/診所和研究機構。區分這些群體可以進行反映推動市場動態的不同目標、資源配置和策略利益的分析。這些細分參數的整合提供了一個全面的觀點，這對於制定有針對性的行銷策略、識別成長機會和最佳化資源配置至關重要。

這些細分之間的相互作用不僅使市場更加清晰，而且還有助於預測未來趨勢和發現個人化治療中尚未開發的市場。這種綜合方法將使技術創新者和政策制定者能夠做出明智的決策，使技術能力與患者需求相結合。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 增加對個人化細胞和基因治療研發的投資和資金
      • 全球遺傳疾病和慢性病的發生率不斷上升
    • 限制因素
      • 與個性化細胞和基因治療相關的複雜而專業的製造程序
    • 機會
      • 開發和整合人工智慧驅動平台，增強細胞和基因治療的個人化
      • 透過製藥公司和生物技術公司之間的策略合作加強個人化醫療
    • 任務
      • 個人化細胞和基因治療領域熟練專家短缺
  • 市場區隔分析
    • 患者類型：脊髓性肌肉萎縮症在兒科患者中的發病率不斷上升，推動了對先進細胞和基因治療的需求
    • 最終用戶：專注於推進下一代治療方法的生物製藥公司
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境

第6章個人化細胞與基因治療市場（依治療類型）

  • 細胞療法
  • 基因治療

7. 個人化細胞和基因治療市場（依患者類型）

  • 成人
  • 老年人
  • 孩子們

第 8 章個性化細胞與基因治療市場（依治療領域）

  • 心臟病學
  • 血液學
  • 免疫學
  • 代謝紊亂
  • 神經病學
  • 腫瘤學
  • 罕見疾病

第9章個人化細胞和基因治療市場（按最終用戶分類）

  • 生物製藥公司
  • 醫院和診所
  • 研究所

10. 美洲個人化細胞與基因治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太個性化細胞與基因治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲個人化細胞和基因治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Adaptimmune Limited
  • Allogene Therapeutics
  • Amgen Inc.
  • Arcellx, Inc.
  • Beam Therapeutics Inc.
  • BioCell Innovations
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Caribou Biosciences, Inc.
  • Celyad Oncology SA
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Fate Therapeutics, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Miltenyi Biomedicine GmbH
  • Novartis AG
  • Sana Biotechnology, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc
Product Code: MRR-1F6B5542A0AC

The Personalized Cell & Gene Therapies Market was valued at USD 13.88 billion in 2024 and is projected to grow to USD 16.30 billion in 2025, with a CAGR of 20.01%, reaching USD 41.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 13.88 billion
Estimated Year [2025] USD 16.30 billion
Forecast Year [2030] USD 41.49 billion
CAGR (%) 20.01%

In the rapidly evolving realm of medicine, personalized cell and gene therapies have emerged as a transformative frontier. The precision offered by these innovative treatments not only redefines therapeutic strategies but also offers unprecedented hope for patients across diverse medical conditions. This introduction sets the stage for a detailed exploration of how these cutting-edge therapies are steering the future of healthcare by tailoring treatments to individual genetic and cellular profiles.

The landscape of biomedicine is shifting from one-size-fits-all solutions to a more nuanced, patient-specific approach. Enter personalized therapies - interventions meticulously designed to work with an individual's own biological characteristics. This approach leverages advances in genomics, biotechnology, and clinical innovations to address complex diseases with higher efficacy and reduced side effects.

As the industry continues to advance, the integration of novel research, sophisticated biotechnology platforms, and strategic partnerships plays a critical role in bridging the gap between clinical potential and practical application. The progression from traditional treatments to personalized solutions is not only fueling clinical breakthroughs but also generating new market opportunities. The following analysis delves deeper into the transformative dynamics, segmentation insights, regional influences, competitive landscapes and strategic recommendations that collectively shape the future of this exciting sector.

Transformative Shifts in the Landscape for Personalized Therapies

Significant transformations have characterized the dynamic evolution of personalized cell and gene therapies over the past decade. Several key drivers have reformed how treatment options are developed, validated, and administered. These drivers include the integration of high-throughput sequencing, advanced bioinformatics, and genome editing technologies that collectively enable more precise therapeutic interventions.

Research breakthroughs have proven fundamental in transitioning from general immunotherapy and chemotherapy to approaches that customize therapeutic interventions at the molecular level. Revolutionary techniques in cellular reprogramming and targeted gene modifications have not only increased the efficacy of treatments but also broadened the spectrum of treatable conditions. As a result, therapies that once were considered out of reach for many patients have now become viable options, adhering to the principle of personalized medicine.

Institutions across the globe are rapidly adopting these innovative methods, capitalizing on increased collaboration between academic research facilities and private-sector companies. This collaboration has refined the processes of drug discovery, clinical translation, and manufacturing scalability. Regulatory bodies are evolving alongside these innovations, implementing streamlined guidelines that facilitate faster approvals while ensuring safety.

These transformative shifts are not merely technological; they are also redefining business models and market strategies. Stakeholders are increasingly investing in platforms that integrate multiomic data to optimize patient selection and enhance treatment precision. Enhanced diagnostic capabilities allow for a more detailed understanding of disease pathways, enabling manufacturers to design therapies that specifically target cellular anomalies. With such rapid advancements, the dichotomy between research and clinical practice is rapidly blurring, leading to a unified approach that benefits both patients and healthcare providers.

Furthermore, the surge in venture capital and private investments underscores the industry's belief in the long-term potential of personalized therapies. These financial infusions have accelerated the pace of innovation, ensuring that the cutting edge of scientific research translates into tangible patient outcomes. As market dynamics continue to evolve, the industry is witnessing a fundamental shift from incremental improvements to radical innovations that redefine healthcare boundaries.

Key Segmentation Insights Driving Market Evolution

An in-depth understanding of market segmentation is key to grasping the breadth and potential of the personalized cell and gene therapies market. The market is comprehensively analyzed along several dimensions that reveal its intricate structure and growth drivers. Initially, segmentation based on therapy type distinguishes between cell therapy and gene therapy, thus providing a dual framework for assessing innovation and application. This classification allows stakeholders to evaluate the distinct technological advancements, regulatory pathways, and clinical outcomes associated with each treatment modality.

Furthermore, segmentation based on patient type stratifies the market into adult, geriatric, and pediatric categories. This classification acknowledges the varying therapeutic needs across different age groups and clinical backgrounds, ensuring that tailored approaches can be effectively applied to each demographic. Patients in each category present unique physiological responses and disease profiles, which in turn necessitate specialized treatment strategies and dosage formulations.

In addition, the segmentation based on therapeutic area offers a detailed examination of the disease landscape by focusing on cardiology, hematology, immunology, metabolic diseases, neurology, oncology, and rare diseases. This multifaceted analysis not only illustrates the diversity of conditions that can be addressed by personalized therapies but also highlights specific areas where breakthroughs are most prominent. Each therapeutic area comes with its own set of challenges and opportunities, influencing investment priorities and research focus.

Lastly, segmentation by end user takes into account various institutional and organizational beneficiaries of this technology, including biopharmaceutical companies, hospitals and clinics, and research institutions. By distinguishing between these groups, the analysis reflects the different objectives, resource allocations, and strategic interests that drive market dynamics. The integration of these segmentation parameters provides a comprehensive perspective that is essential for formulating targeted marketing strategies, identifying growth opportunities, and optimizing resource allocation.

The interplay between these segmentation dimensions not only enhances market clarity but also aids in predicting future trends and identifying underexploited niches within the personalized therapies landscape. This integrated approach ensures that both innovators and policymakers can make informed decisions that align technological capabilities with patient needs.

Based on Therapy Type, market is studied across Cell Therapy and Gene Therapy.

Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.

Based on Therapeutic Area, market is studied across Cardiology, Hematology, Immunology, Metabolic Diseases, Neurology, Oncology, and Rare Diseases.

Based on End User, market is studied across Biopharmaceutical Companies, Hospitals & Clinics, and Research Institutions.

Key Regional Insights Illuminating Global Trends

Geographic analysis plays a pivotal role in understanding the current progress and future potential of the personalized cell and gene therapies market. Studies reveal that the evolution of these therapies is being driven by diverse market dynamics and regulatory frameworks across various global regions. In North and South America, robust investment in biotechnology research and the presence of leading academic institutions have catalyzed significant advancements. The region has demonstrated a proactive stance in regulatory approvals and clinical validations, thereby setting benchmarks that motivate similar progress in other parts of the world.

Across Europe, the Middle East and Africa, the adoption of personalized therapies is coupled with strategic government incentives and collaborative research initiatives. European nations, in particular, have established comprehensive frameworks that combine public and private investments, leading to accelerated market penetration. Middle Eastern and African regions are gradually building capacities and are poised to benefit from knowledge transfers and technological partnerships, promising a steady upward trajectory in accessing these advanced treatments.

In the Asia-Pacific, there is an observable transformation underpinned by increasing government support, favorable regulatory reforms, and burgeoning research ecosystems. The rapid growth of biotechnology start-ups and the expansion of clinical trial networks in this region have cultivated an environment that is highly conducive to innovation. The integration of advanced telemedicine and health informatics further complements these developments, ensuring that personalized therapies reach a wider, more diverse patient base.

Collectively, these regional insights underscore the importance of localized strategies that respond to unique regulatory, economic, and cultural variables. Understanding these differences is crucial for stakeholders aiming to deploy customized market strategies. These insights further illustrate how cross-border collaborations and technology exchanges can facilitate the broader adoption of personalized cell and gene therapies on a global scale, adapting to the dynamic needs of each region while supporting overall market growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Within Personalized Therapies

The competitive landscape in personalized cell and gene therapies is characterized by a dynamic roster of pioneering companies working to revolutionize treatment modalities. Market leaders such as Adaptimmune Limited, Allogene Therapeutics, Amgen Inc., Arcellx, Inc., and Beam Therapeutics Inc. are at the forefront of developing innovative treatment platforms that harness the power of cellular engineering and genome editing. These companies continuously invest in cutting-edge research and clinical trials to push the boundaries of therapeutic capabilities.

Emerging innovators like BioCell Innovations and bluebird bio, Inc. have built robust pipelines that strive to address previously unreachable therapeutic areas, while established names like Bristol-Myers Squibb Company and Caribou Biosciences, Inc. are leveraging decades of experience in the pharmaceutical industry to bring personalized treatments to market. Companies such as Celyad Oncology SA and CRISPR Therapeutics AG have refined their approaches to gene editing, marking significant milestones in the effective treatment of complex diseases.

The landscape is further enriched by entities including Editas Medicine, Inc., Fate Therapeutics, Inc., Genentech, Inc., and Gilead Sciences, Inc., each contributing uniquely to the science and commercialization of personalized therapies. Intellia Therapeutics, Inc. and Lonza Group Ltd. bring state-of-the-art manufacturing innovations that are crucial in scaling up production. Miltenyi Biomedicine GmbH, Novartis AG, Sana Biotechnology, Inc., Sangamo Therapeutics, Inc., and Sarepta Therapeutics, Inc. have also been instrumental in addressing regulatory challenges and ensuring that new therapies adhere to the highest quality standards.

The continued evolution and competitive nature of this market necessitate an emphasis on collaboration and the sharing of technological advancements. These key players, with their extensive research, robust technological portfolios, and strategic foresight, collectively drive industry benchmarks and contribute to the rapid pace of market evolution. Their interplay not only stimulates healthy competition but also fuels innovation and broadens the potential for future therapeutic breakthroughs.

The report delves into recent significant developments in the Personalized Cell & Gene Therapies Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Limited, Allogene Therapeutics, Amgen Inc., Arcellx, Inc., Beam Therapeutics Inc., BioCell Innovations, bluebird bio, Inc., Bristol-Myers Squibb Company, Caribou Biosciences, Inc., Celyad Oncology SA, CRISPR Therapeutics AG, Editas Medicine, Inc., Fate Therapeutics, Inc., Genentech, Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Miltenyi Biomedicine GmbH, Novartis AG, Sana Biotechnology, Inc., Sangamo Therapeutics, Inc., and Sarepta Therapeutics, Inc. Actionable Recommendations for Industry Leaders to Drive Market Growth

For decision-makers and executives operating within the personalized therapies market, adopting a proactive and adaptive strategy is pivotal to navigating the complex landscape. It is imperative to leverage detailed segmentation analyses to identify underserved patient groups and emerging therapeutic areas. By aligning R&D initiatives with these specific market segments, industry leaders can ensure that their portfolios are both innovative and responsive to real-world clinical needs.

A collaborative approach is equally critical. Strategic partnerships between biopharmaceutical companies, research institutions, and healthcare providers can accelerate the translation of laboratory breakthroughs into clinically effective solutions. Investing in joint ventures and co-development projects paves the way for shared resources and mutual learning, thereby reducing the risk and speeding up time-to-market for new therapies.

Industry players should also focus on expanding their geographic footprint by tailoring market entry strategies to the specific regulatory and cultural landscapes of different regions. Emphasizing the synergistic opportunities present in high-investment regions such as those in the Americas, as well as emerging markets in Europe, the Middle East, Africa, and Asia-Pacific, will play a pivotal role in driving sustained growth.

Moreover, integrating advanced analytics and real-world evidence into decision-making processes can refine forecasting models and enhance patient selection criteria. Utilizing data-driven insights not only optimizes clinical trial designs but also improves overall therapeutic outcomes by ensuring that treatments meet the precise needs of diverse patient groups.

Finally, establishing a robust commercial strategy that includes dynamic pricing models, comprehensive patient education programs, and proactive engagement with regulatory authorities can provide a competitive edge. By continuously monitoring market trends and investing in long-term innovation, leaders can mitigate uncertainty and capitalize on emerging opportunities within this rapidly evolving domain.

Conclusion: Shaping the Future of Personalized Cellular and Genetic Therapies

The journey through the evolving landscape of personalized cell and gene therapies reveals a sector on the cusp of unprecedented transformation. With advancements in biotechnology, innovative research practices, and strategic collaborations, personalized therapies are paving the way towards more effective, targeted treatments that can dramatically improve patient outcomes. The convergence of technological breakthroughs with market-driven insights, detailed segmentation analysis, and regional trends highlights a vibrant ecosystem that is both dynamic and forward-thinking.

As industry leaders navigate this complex terrain, the importance of adaptability and collaboration cannot be overstated. Companies are steadily moving towards embracing integrated approaches that combine state-of-the-art research, patient-centric strategies, and robust manufacturing processes. This multi-dimensional strategy not only aids in addressing current clinical challenges but also sets a foundation for future innovation in treating a diverse array of diseases.

The convergence of strategic partnerships, regulatory support, and ever-evolving technological landscapes ensures that the field remains dynamic, equipped to meet both present and future challenges. In summing up, personalized cell and gene therapies are not merely an incremental improvement over traditional treatment paradigms; they represent a fundamental shift in how diseases are understood and treated, with implications that extend well beyond the laboratory. The insights garnered from this comprehensive analysis provide industry stakeholders with the tools needed to harness the full potential of these transformative therapies as they collectively shape the future of medicine.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing investments and funding in research and development of personalized cell and gene therapies
      • 5.1.1.2. Increasing prevalence of genetic disorders and chronic diseases globally
    • 5.1.2. Restraints
      • 5.1.2.1. Complex and specialized manufacturing processes associated with personalized cell & gene therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development and integration of AI-driven platforms to enhance cell and gene therapy personalization
      • 5.1.3.2. Strategic collaborations between pharma and biotech companies to enhance personalized therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled professionals in personalized cell and gene therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Patient Type: Growing prevalence of spinal muscular atrophy among pediatric patients boosts demand for advanced cell gene therapies
    • 5.2.2. End User: Biopharmaceutical companies focusing on advancing next-generation therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Personalized Cell & Gene Therapies Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Gene Therapy

7. Personalized Cell & Gene Therapies Market, by Patient Type

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Geriatric
  • 7.4. Pediatric

8. Personalized Cell & Gene Therapies Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Hematology
  • 8.4. Immunology
  • 8.5. Metabolic Diseases
  • 8.6. Neurology
  • 8.7. Oncology
  • 8.8. Rare Diseases

9. Personalized Cell & Gene Therapies Market, by End User

  • 9.1. Introduction
  • 9.2. Biopharmaceutical Companies
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutions

10. Americas Personalized Cell & Gene Therapies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Personalized Cell & Gene Therapies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Personalized Cell & Gene Therapies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. NIH's precision medicine trial seeks to revolutionize treatment for myeloid cancers with genetic targeting advancements
    • 13.3.2. Aspen Neuroscience expands San Diego manufacturing hub to accelerate personalized cell therapies for Parkinson's Disease treatment
    • 13.3.3. FDA Approval of Breyanzi as First CAR T Cell Therapy Signals Advancement for Relapsed CLL and SLL
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Limited
  • 2. Allogene Therapeutics
  • 3. Amgen Inc.
  • 4. Arcellx, Inc.
  • 5. Beam Therapeutics Inc.
  • 6. BioCell Innovations
  • 7. bluebird bio, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Caribou Biosciences, Inc.
  • 10. Celyad Oncology SA
  • 11. CRISPR Therapeutics AG
  • 12. Editas Medicine, Inc.
  • 13. Fate Therapeutics, Inc.
  • 14. Genentech, Inc.
  • 15. Gilead Sciences, Inc.
  • 16. Intellia Therapeutics, Inc.
  • 17. Lonza Group Ltd.
  • 18. Miltenyi Biomedicine GmbH
  • 19. Novartis AG
  • 20. Sana Biotechnology, Inc.
  • 21. Sangamo Therapeutics, Inc.
  • 22. Sarepta Therapeutics, Inc

LIST OF FIGURES

  • FIGURE 1. PERSONALIZED CELL & GENE THERAPIES MARKET MULTI-CURRENCY
  • FIGURE 2. PERSONALIZED CELL & GENE THERAPIES MARKET MULTI-LANGUAGE
  • FIGURE 3. PERSONALIZED CELL & GENE THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 4. PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. PERSONALIZED CELL & GENE THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. PERSONALIZED CELL & GENE THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERSONALIZED CELL & GENE THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PERSONALIZED CELL & GENE THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. PERSONALIZED CELL & GENE THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 195. PERSONALIZED CELL & GENE THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024